Bringing AAPS to You - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bringing AAPS to You
Pharmaceutical Technology will feature video coverage of AAPS this month.


Pharmaceutical Technology
Volume 32, Issue 11, pp. 14


Patricia Van Arnum
Like many readers of Pharmaceutical Technology, I will be attending the annual meeting and exhibition of the American Association of Pharmaceutical Scientists (AAPS) in Atlanta, on Nov. 16–20. AAPS always provides a great opportunity to hear the leading minds in the pharmaceutical sciences, and PharmTech will be building on that tradition through a new project that we are launching at AAPS.

Michelle Hoffman, editor-in-chief, Maribel Rios, senior editor, and I will interview session speakers and other industry thought leaders live at the PharmTech booth (Number 1331). These interviews will make up our Vidcast program, which will be posted here and delivered in special AAPS editions of ePT, Pharmaceutical Technology's weekly electronic newsletter.

Moheb Nasr, director of FDA's Office of New Drug Quality Assessment, will discuss FDA's quality-by-design (QbD) initiative as it applies to analytical methods. Excipient manufacturers will offer their views on QbD and how to achieve better process understanding.

Experts will also explain the potential of liquid-filled hard capsules, including their use in early clinical studies as a quick-to-market option, and the promise of nanotechnology in drug delivery. Industry leaders will discuss the fundamentals of particles and powders and the characteristics needed to produce a quality solid dosage form. Speakers will also explain how approaches such as hot-melt extrusion, nanocrystals, and spray-dried solid dispersions can overcome poor solubility. And AAPS President Karen Habucky will share her views on education for pharmaceutical scientists and engineers.

So tune in here for the latest from AAPS.

Patricia Van Arnum is a senior editor of Pharmaceutical Technology.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here